Loading…
Chinese biopharma discovering small-molecule drugs in neuropsychiatry, reproductive health and viral infection, incl. antiviral VV116.
Chinese biopharma discovering small-molecule drugs in neuropsychiatry, reproductive health and viral infection, incl. antiviral VV116.
Partner Junshi sells VV116, its antiviral for COVID, in China under a license, so Vigonvita is paid through milestones and a share of sales rather than selling it itself. Sales of such drugs depend heavily on infection waves, which have eased since the pandemic.
In one line: A small Chinese antiviral/CNS drug developer.
Moat: narrow (IP / patents, regulatory licence). Owns IP on approved antiviral/CNS molecules and out-licenses commercialization rights.
Headquarters: Suzhou, China · Founded: 2013
Size Vigonvita Life Sciences (2630.HK) is a Hong Kong Health Care company (Pharmaceuticals: Generic) with a market value of $1.48B, the 495th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$69.20 on 6 Nov 2026.
Performance Over six months the shares fell 10.7%, against -16.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd highest of 7 in its peer set.
Growth Revenue grew 763.1% over the last twelve months (peer median -5.0%); the operating margin is -327.4% (peer median 0.5%).
Valuation It trades at 109.3× enterprise value to sales against a peer median of 12.8× (most expensive of 7).
Capital Return on invested capital runs 58.3 points below its cost of capital (17.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | HK$111M | HK$12.8M | HK$221M |
| Revenue growth | — | +763% | -94% | — |
| Gross profit | n/a | HK$61.9M | -HK$26.7M | HK$214M |
| EBITDA | n/a | -HK$318M | -HK$186M | n/a |
| Net income | n/a | -HK$386M | -HK$229M | HK$13.4M |
| Free cash flow | n/a | -HK$299M | -HK$218M | n/a |
| Capital expenditure | n/a | HK$178M | HK$95.6M | n/a |
| Total debt | n/a | HK$720M | HK$443M | HK$365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vigonvita Life Sciences 2630.HK | $1.48B | -11% | +763% | -327% | 109.3× | n/a |
| Shanghai Junshi Biosciences 1877.HK | $4.08B | -39% | +36% | -14% | 9.6× | n/a |
| Simcere Pharmaceutical 2096.HK | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | $8.69B | -10% | +10% | 6% | 2.4× | 20.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2630.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -9.7% | 3rd lowest of 7 |
| 6-month return | -10.7% | -16.4% | 3rd highest of 7 |
| Distance from 52-week high | -48.7% | -40.1% | 3rd lowest of 7 |
| Revenue growth (TTM) | +763.1% | -5.0% | highest of 7 |
| Operating margin | -327.4% | 0.5% | lowest of 6 |
| EV / Sales | 109.3× | 12.8× | most expensive of 7 |
| ROIC minus cost of capital | -58.3 pp | -3.5 pp | 2nd lowest of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | 109.3× | n/a | n/a |
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 38.3× | n/a | n/a |
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | 34.1× | n/a | n/a |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | 1.0× | 17.7% | -23.1% |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | 21.8× | n/a | n/a |
| Hikma Pharmaceuticals HIK.L | United Kingdom | $4.59B | +18% | +2% | 20% | 1.8× | 1.4% | +6.8% |
| Zhejiang Shouxiangu Pharmaceutical 603896.SS | China | $398M | -22% | -10% | n/a | 3.9× | n/a | n/a |